beta
Trial Radar AI
Clinical Trial NCT06844110 for Tumor Immunity is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor 50 Targeted Therapy

Recruiting
Clinical Trial NCT06844110 is an interventional study for Tumor Immunity that is recruiting. It started on 1 March 2025 with plans to enroll 50 participants. Led by Peking Union Medical College Hospital, it is expected to complete by 30 March 2026. The latest data from ClinicalTrials.gov was last updated on 5 August 2025.
Brief Summary
68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73. At the same time, correlation analysis was performed combined with relevant clinical indicators to evaluate the efficacy of 68Ga-DOTA-dPNE in the diagnosis and guidance of malignant tumor patients, and predict the response of targeted therapy.
Official Title

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor

Conditions
Tumor Immunity
Other Study IDs
  • PUMCH-NM-CD73-2
NCT ID Number
NCT06844110
Start Date (Actual)
2025-03-01
Last Update Posted
2025-08-05
Completion Date (Estimated)
2026-03-30
Enrollment (Estimated)
50
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Primary Purpose
Diagnostic
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalMalignant tumor
68GA-DOTA-dPNE
Intravenous administration of 68GA-DOTA-dPNE tracer
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Lesion SUV value
After the completion of the PET scan
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  • 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up

- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study.

3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study

Peking Union Medical College Hospital logoPeking Union Medical College Hospital482 active studies to explore
Study Central Contact
Contact: Chenhao Jia, 18548703382, [email protected]
1 Study Locations in 1 Countries

Beijing Municipality

PUMCH, Dongcheng, Beijing Municipality, 100730, China
Chenhao JIA, Contact, 18548703382, [email protected]
Recruiting